RecruitingPHASE2, PHASE3NCT04912843
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
Studying Hereditary optic neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wuhan Neurophth Biotechnology Limited Company
- Principal Investigator
- Bin Li, MDWuhan Neurophth Biotechnology Limited Company
- Intervention
- NR082 injection(drug)
- Enrollment
- 102 enrolled
- Eligibility
- 12-75 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- Beijing Tongren Hospital, Capital Medical University, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04912843 on ClinicalTrials.gov